|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
CA2205572A1
(en)
|
1994-12-12 |
1996-06-20 |
Beth Israel Hospital Association |
Chimeric cytokines and uses thereof
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
EP2292273A3
(en)
|
2001-10-10 |
2011-11-23 |
BioGeneriX AG |
Remodeling and glycoconjugation of peptides
|
|
AU2003210806A1
(en)
|
2002-03-05 |
2003-09-22 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
SI1624891T2
(sl)
|
2003-05-06 |
2013-09-30 |
Biogen Idec Hemophilia Inc. |
Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
|
|
ES2371072T3
(es)
|
2003-06-12 |
2011-12-27 |
Eli Lilly And Company |
Proteínas de fusión análogas de glp-1.
|
|
EP1699821B1
(en)
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
US7982010B2
(en)
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
|
US7985839B2
(en)
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
|
WO2007126808A1
(en)
|
2006-03-31 |
2007-11-08 |
Baxter International Inc |
Pegylated factor viii
|
|
WO2008077616A1
(en)
|
2006-12-22 |
2008-07-03 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
MX2009007145A
(es)
|
2006-12-27 |
2009-08-27 |
Nektar Therapeutics Al Corp |
Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
|
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
|
BRPI0814220B8
(pt)
|
2007-07-11 |
2021-05-25 |
Novo Nordisk As |
purificação de fator viii usando uma resina multimodal ou de modo misto
|
|
AU2008323768A1
(en)
|
2007-11-09 |
2009-05-14 |
Baxter Healthcare S.A. |
Modified recombinant Factor VIII and von Willebrand Factor and methods of use
|
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
|
PT2349342T
(pt)
|
2008-10-17 |
2018-10-26 |
Baxalta Inc |
Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
|
|
WO2010087271A1
(ja)
|
2009-01-28 |
2010-08-05 |
日本電気株式会社 |
不揮発ロジック回路
|
|
US20110306551A1
(en)
|
2009-02-19 |
2011-12-15 |
Novo Nordisk A/S |
Modification of Factor VIII
|
|
ES2427627T3
(es)
|
2009-04-06 |
2013-10-31 |
Novo Nordisk A/S |
Entrega dirigida de proteínas de Factor VIII a plaquetas
|
|
RU2579977C2
(ru)
|
2009-11-13 |
2016-04-10 |
Грифольс Терапьютикс Инк. |
СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
|
|
WO2011101284A1
(en)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Factor viii fusion protein
|
|
EP2536753B1
(en)
|
2010-02-16 |
2017-12-20 |
Novo Nordisk A/S |
Factor viii molecules with reduced vwf binding
|
|
US9234192B2
(en)
|
2010-02-16 |
2016-01-12 |
Novo Nordisk A/S |
Conjugated proteins
|
|
WO2011131510A2
(en)
|
2010-04-21 |
2011-10-27 |
Novo Nordisk A/S |
Selective modification of proteins
|
|
JP2013532176A
(ja)
|
2010-07-15 |
2013-08-15 |
ノヴォ ノルディスク アー/エス |
安定化させた第viii因子バリアント
|
|
AU2011289579B2
(en)
*
|
2010-08-10 |
2016-11-17 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
AU2012340501A1
(en)
|
2011-12-19 |
2013-07-11 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
HRP20191920T1
(hr)
|
2012-01-12 |
2020-01-10 |
Bioverativ Therapeutics Inc. |
Kimerni polipeptidi faktora viii i njihova uporaba
|
|
US9458223B2
(en)
|
2012-02-15 |
2016-10-04 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor VIII binding affinity
|
|
CA2864432A1
(en)
|
2012-02-15 |
2013-08-22 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
US20150080309A1
(en)
|
2012-04-24 |
2015-03-19 |
Nova Nordisk A/S |
Compounds Suitable for Treatment of Haemophilia
|
|
US9879090B2
(en)
|
2013-03-04 |
2018-01-30 |
INSERM (Institut National De La SantéEt De La Recherche Médicale |
Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
|
|
WO2014198699A2
(en)
|
2013-06-12 |
2014-12-18 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
|
DK3164150T3
(da)
*
|
2014-07-02 |
2021-02-08 |
CSL Behring Lengnau AG |
Modificeret von willebrand-faktor
|
|
SG11201706659WA
(en)
*
|
2015-03-06 |
2017-09-28 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
|
SG11201805494WA
(en)
|
2016-01-07 |
2018-07-30 |
Csl Behring Recombinant Facility Ag |
Mutated von willebrand factor
|
|
AU2017204955B2
(en)
|
2016-01-07 |
2021-04-01 |
CSL Behring Lengnau AG |
Mutated truncated von Willebrand Factor
|
|
JP2020504082A
(ja)
|
2016-11-11 |
2020-02-06 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
|
|
JP2020504084A
(ja)
*
|
2016-11-16 |
2020-02-06 |
バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC |
赤血球標的化第viii因子およびその使用方法
|
|
DK3641800T5
(da)
*
|
2017-06-22 |
2024-08-26 |
CSL Behring Lengnau AG |
Modulation af fviii immunogenicitet ved trunkeret vwf
|
|
WO2019075523A1
(en)
|
2017-10-20 |
2019-04-25 |
Csl Ltd. |
PROCESS
|